TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ImmuPharma ( (GB:IMM) ) has issued an update.
ImmuPharma PLC announced its final results for 2024, highlighting significant advancements in its P140 autoimmune technology platform. The company reported a reduced loss for the period and a successful fundraising effort. Key developments include groundbreaking preclinical research that enhances diagnostics and treatment monitoring for autoimmune diseases, and evidence supporting P140’s unique mechanism of action, which is non-immunosuppressive. These advancements have strengthened ImmuPharma’s intellectual property portfolio and opened discussions with potential global commercial partners, positioning the company for future growth and impact in the autoimmune disease treatment market.
More about ImmuPharma
ImmuPharma PLC is a specialist drug discovery and development company focused on creating innovative therapies for autoimmune diseases. The company’s primary product is the P140 technology platform, which aims to provide novel treatments for conditions such as systemic lupus erythematosus (SLE) by restoring immune system balance.
Average Trading Volume: 3,086,600
Technical Sentiment Signal: Buy
Current Market Cap: £16.77M
See more data about IMM stock on TipRanks’ Stock Analysis page.